Clinical Assessment & Management Analysis

Patient Summary

• 17-year-old male, mixed P. falciparum + P. vivax infection
• BP 90/60 mmHg | HR 140/min | RR 26/min | Temp 100°F
• Platelets 54,000/μL | Right hypochondriac pain | 2 episodes vomiting
• Conscious and coherent
• Started on: Falcigo (artesunate) IV + Doxycycline + 1L IV fluid bolus → 125 ml/hr maintenance + Paracetamol 1g

Step 1: Severity Classification — Is This Severe Malaria?

Step 2: Is Current Treatment Appropriate?

✅ Artesunate (Falcigo) IV — CORRECT and APPROPRIATE

• Standard: 2.4 mg/kg IV at 0 h, 12 h, 24 h, then once daily (for children <20 kg: 3 mg/kg/dose)
• At 17 years (assuming ~50–60 kg), dose should be ~120–144 mg per injection
• Confirm the ordered dose is weight-based

✅ Doxycycline — APPROPRIATE as partner drug

⚠️ Important: Doxycycline should ideally be given after, not concurrently with, the acute parenteral phase, or if given orally alongside, only once the patient can reliably retain oral medications (currently vomiting — hold oral doxy until vomiting controlled).

✅ IV Fluids — APPROPRIATE but needs caution

• Avoid large-volume fluid boluses in severe malaria — trials showed excess mortality with aggressive volume loading due to pulmonary edema risk
• 125 ml/hr maintenance is reasonable
• Monitor urine output closely (target ≥0.5 ml/kg/hr)
• If oliguria develops despite fluids → suspect acute kidney injury → early hemofiltration/dialysis

✅ Paracetamol 1g — APPROPRIATE for fever

Step 3: What Is Missing / Needs Attention

🔴 Anti-vivax / Radical Cure — NOT yet addressed

1. Acute phase: Artesunate covers vivax blood-stage parasites — acceptable
2. Radical cure (hypnozoites): Primaquine 0.25–0.5 mg/kg/day × 14 days is required to prevent relapse, BUT:
   • Check G6PD status FIRST before giving primaquine — hemolytic anemia risk
   • Start primaquine only after acute illness resolves and G6PD result is available
   • In G6PD deficiency: weekly primaquine 0.75 mg/kg × 8 weeks or tafenoquine (≥16 years)

🔴 Monitoring — ICU-level surveillance needed

• Hourly BP, HR, SpO₂
• 6-hourly or daily blood glucose (artesunate + falciparum → hypoglycemia risk)
• Renal function: creatinine, urea, urine output
• Blood film / RDT at 24 h, 48 h, 72 h (parasite clearance)
• LFTs (RHC pain → hepatic involvement)
• CBC daily (thrombocytopenia monitoring, hemolysis)
• Electrolytes

🔴 Manage Hypotension Actively

• If BP does not improve with 1L bolus → add vasopressor (norepinephrine) carefully
• Rule out concurrent sepsis/bacteremia — broad-spectrum antibiotics (e.g. ceftriaxone) should be considered given difficulty distinguishing severe malaria from co-existing sepsis, especially in children/adolescents (Harrison's 22E)

🟡 Anti-emetics

🟡 Platelet Transfusion

🟡 Oral Step-Down

• Once patient is stable, not vomiting, and has had ≥24h of parenteral artesunate → switch to oral ACT (e.g. artemether-lumefantrine) + complete doxycycline 7-day course
• Do not switch before 24h minimum of IV treatment regardless of clinical improvement

🟡 Avoid Adjunctive Harmful Treatments

Step 4: Summary Action Plan

Overall Verdict

Sources: Harrison's Principles of Internal Medicine 22E (2025), WHO Guidelines for Malaria (updated 2024), Swiss TPH Malaria Treatment Recommendations 2025

Role of LDH, Lactate, Electrolytes, and ABG in This Patient

1. LDH (Lactate Dehydrogenase)

Why it's elevated in malaria

• P. falciparum invades and ruptures RBCs at schizogony — each rupture releases intracellular LDH into plasma
• LDH is the most abundant enzyme in RBCs; even moderate hemolysis causes marked elevation
• Mixed infection (P. vivax also causes RBC lysis) amplifies this

• When oxygen delivery fails (as in this patient with shock: BP 90/60, HR 140), cells switch to anaerobic glycolysis → pyruvate → lactate, catalyzed by LDH
• Elevated LDH therefore also reflects end-organ hypoperfusion

What to do with it clinically

PADH — a specific complication of IV artesunate in heavy parasite loads: stored, drug-altered RBCs that initially "pitted" parasites re-enter circulation and are later destroyed by the spleen, causing a hemolytic dip at 1–3 weeks post-treatment. Monitor LDH + Hb at days 7, 14, 21.

2. Lactate

The mechanism in severe malaria

1. Cytoadherence & sequestration: Falciparum-infected RBCs express PfEMP1 and adhere to microvascular endothelium → microvascular obstruction → local tissue hypoxia → anaerobic glycolysis → lactic acidosis
2. Shock physiology: This patient's hypotension (BP 90/60) + tachycardia (HR 140) = reduced cardiac output → global oxygen delivery failure → type A lactic acidosis
3. Parasite metabolism: P. falciparum itself is an obligate lactate producer — the parasite ferments glucose at up to 75× the rate of host RBCs, directly dumping lactate into blood
4. Hepatic clearance failure: The liver is the main organ clearing lactate; hepatic involvement (this patient has RHC pain) impairs lactate clearance, worsening acidosis

Clinical interpretation

What to do

• Measure lactate NOW — this is a key prognostic marker in severe malaria
• Serial lactate at 2–4 hourly intervals — clearance of lactate (>10% fall per 2h) signals effective resuscitation
• Lactate-guided resuscitation: if lactate remains elevated despite fluids, escalate to vasopressors (norepinephrine)
• Do not use bicarbonate to treat lactic acidosis in malaria — treats the number, not the cause, and may worsen cerebral edema

3. Electrolytes

Sodium (Na⁺)

• Hyponatremia is common in severe malaria
• Mechanism: cytokine-mediated SIADH, volume redistribution, vomiting losses (this patient — 2 episodes)
• Dilutional effect from IV fluid resuscitation (1L NS given)
• Clinical risk: hyponatremia contributes to cerebral edema, seizure risk
• Target: Na 135–145 mEq/L; correct slowly if chronic

Potassium (K⁺)

• Can go either way:
  • Hyperkalemia from massive hemolysis (intracellular K⁺ release) — especially dangerous with acute kidney injury
  • Hypokalemia from vomiting, poor intake, shift into cells with insulin/glucose administration
• Must monitor — hyperkalemia + acidosis + AKI is a life-threatening triad

Bicarbonate (HCO₃⁻)

• Low HCO₃⁻ is a direct marker of metabolic acidosis severity
• Acts as buffer against lactic acid
• Level <15 mEq/L = severe acidosis; <10 mEq/L = life-threatening
• Use the HCO₃⁻ value from electrolytes to calculate anion gap (see ABG below)

Phosphate (PO₄³⁻)

• Hypophosphatemia is specifically named in Harrison's as a feature of severe malaria
• Mechanism: intracellular shift, poor intake, refeeding, tubular losses in AKI
• Severe hypophosphatemia (<1 mg/dL) → impaired ATP synthesis → muscle weakness, respiratory failure risk

Glucose

• Hypoglycemia is a major, life-threatening complication of severe malaria
• Caused by: parasite glucose consumption + quinine/artesunate-stimulated insulin secretion + impaired hepatic gluconeogenesis
• Check glucose every 4–6 hours; maintain >70 mg/dL with D10 infusion if needed

4. Arterial Blood Gas (ABG)

Expected ABG pattern in this patient

• Lactic acidosis from tissue hypoxia + parasite lactate production
• Loss of HCO₃⁻ from vomiting (partially offsetting)
• Anion gap = Na − (Cl + HCO₃); expected to be elevated (>12–14 mEq/L) → HAGMA

• RR 26 in this patient = hyperventilation — the body's attempt to blow off CO₂ and raise pH
• This is Kussmaul-type breathing when severe
• Expected PaCO₂: use Winter's formula → PaCO₂ = 1.5 × (HCO₃) + 8 ± 2
  • If actual PaCO₂ < expected → additional primary respiratory alkalosis
  • If PaCO₂ > expected → coexisting respiratory acidosis (respiratory failure — very bad sign)

• If the patient tires and cannot maintain hyperventilation → PaCO₂ rises → pH crashes
• Rising PaCO₂ with falling pH = impending respiratory failure → intubation threshold

ABG parameters and their specific roles

Action thresholds from ABG

• pH <7.2 + PaCO₂ rising: prepare for intubation / ICU escalation
• PaO₂ <60 mmHg on room air: start supplemental O₂; if not improving → face mask/HFNC
• BE < −10: aggressive fluid and lactate clearance protocol
• HCO₃ <10: severe buffer depletion — reassess resuscitation urgently

Summary: What to Order and Why

Source: Harrison's Principles of Internal Medicine 22E (2025) — "Laboratory Findings in Acute Malaria"; WHO Guidelines for Malaria 2024

Procalcitonin 16 ng/mL + Antibiotic Decision-Making

Step 1: Interpret the PCT of 16 in Context

PCT is elevated in severe malaria itself — not just bacterial co-infection

• P. falciparum cytokine storm (TNF-α, IL-6, IL-1β) drives PCT production even without bacteria
• Degree of parasitemia, hemolysis, and host immune status all independently elevate PCT
• PCT does not differentiate malaria-driven inflammation from true bacteremia

Does this mean there is no bacterial co-infection?

Key question to ask before escalating:

Step 2: Why Cefoperazone-Sulbactam Was Chosen (and Its Limits)

• Enterobacteriaceae (ESBL coverage through sulbactam component)
• Pseudomonas aeruginosa (moderate activity)
• Acinetobacter baumannii (sulbactam has intrinsic anti-Acinetobacter activity)
• Anaerobes (reasonable)

• KPC-producing Klebsiella and other carbapenem-resistant Enterobacteriaceae (CRE)
• MBL (metallo-β-lactamase) producers
• High-level ESBL with inoculum effect
• MRSA (no gram-positive coverage)

Step 3: Comparing the Three Options

Option A: Meropenem

Option B: Cefepime + Tazobactam (Fetroja-like combination, though usually listed as cefepime/tazobactam = fixed combination in development; in practice often means piperacillin-tazobactam paired with cefepime, or you may mean cefepime alone as escalation)

⚠️ Clarification: "Cefepime + tazobactam" as a combined agent (cefepime-tazobactam) is a newer fixed combination (FDC) still in late trials in some countries. If you mean piperacillin-tazobactam (pip-tazo), that is a separate drug. If you mean adding tazobactam to cefepime as separate IV infusions — that is not standard. Please clarify. The analysis below covers cefepime and pip-tazo separately.

• 4th gen cephalosporin — covers ESBL (partially), AmpC-producing organisms, Pseudomonas
• Inferior to carbapenems for high-inoculum ESBL infections
• Does NOT cover KPC, Acinetobacter, anaerobes

• Broad gram-negative + anaerobe coverage
• ESBL coverage is unreliable (inoculum effect — clinical failures reported despite in vitro sensitivity)
• The MERINO trial (2018) showed pip-tazo was non-inferior to meropenem for E. coli/Klebsiella ESBL bacteremia — but with numerically higher 30-day mortality (12.3% vs 3.7%), leading to many centres preferring carbapenems for ESBL bacteremia
• Good Pseudomonas coverage
• No CRE activity

Option C: Ceftazidime-Avibactam + Aztreonam

Step 4: Decision Framework for This Patient

PCT = 16 ng/mL
         ↓
Attributable to severe malaria alone? (PCT 14.13 expected)
         ↓
Are blood cultures available / pending?
         ↓
Is cefoperazone-sulbactam failing clinically?
(persisting fever/shock NOT improving after 48–72h antimalarials)
         ↓
Any source of infection identified?

Scenario-Based Recommendation

Step 5: Practical Recommendation for This Patient

• 17-year-old, severe malaria, PCT 16 (expected for severe malaria)
• Already on cefoperazone-sulbactam (reasonable empiric gram-negative cover)
• No culture data mentioned
• Source of bacterial infection unclear

Immediate actions before escalating:

1. Send blood cultures × 2 sets (if not done) — this is non-negotiable before changing antibiotics
2. Urine culture — UTI/urosepsis common secondary infection in severe malaria
3. Chest X-ray — aspiration pneumonia (2 episodes vomiting), hospital-acquired pneumonia
4. Reassess at 48–72h: if fever resolving with antimalarials and no positive culture → PCT rise is malaria-driven, no escalation needed

If escalation is clinically warranted:

• First choice: Meropenem 1g IV q8h (or 2g q8h extended infusion if severe)
  • Covers ESBL, CRE (KPC), Pseudomonas, Acinetobacter, anaerobes
  • Best CNS penetration (relevant given severe malaria cerebral risk)
  • Most evidence-based option for severe undifferentiated sepsis
  • Replace cefoperazone-sulbactam with meropenem (don't combine unnecessarily)
• Reserve ceftazidime-avibactam + aztreonam for: culture-confirmed CRE/MBL, or failure of meropenem — not for empiric use in this scenario
• Cefepime ± tazobactam: a reasonable de-escalation choice once cultures show susceptible gram-negatives; not an escalation from cef-sulbactam

Summary Box

Sources: Harrison's Principles of Internal Medicine 22E (Sepsis Management); Harriet Lane Handbook 23rd Ed; Mahittikorn et al., Meta-Analysis on PCT in Malaria, PMID 36141662

Refractory Hypotension on Noradrenaline — What to Do Now

First: Define What's Happening

• BP 90/60 → MAP = (90 + 2×60)/3 = 70 mmHg — technically meets the MAP ≥65 target
• But HR 140 + lactate 3.2 + noradrenaline dependence = this is still septic shock by Sepsis-3 criteria

Step-by-Step Escalation (Surviving Sepsis Campaign / Harrison's 22E)

1. Confirm Fluid Status First

• Passive leg raise (PLR): raise legs 45° × 1 min — if MAP rises >10% or pulse pressure increases, patient is still fluid-responsive → give another 250–500 mL crystalloid bolus (balanced solution — lactated Ringer's preferred over NS to avoid hyperchloraemic acidosis)
• But avoid fluid overload — malaria specifically increases risk of pulmonary edema. If CVP >12, patient is not preload-responsive; adding more fluid causes harm
• Point-of-care echo (POCUS): IVC collapsibility, LV function — if available

2. Add Vasopressin (Second-Line Vasopressor)

"Vasopressin should be added as a second agent... to maintain a mean arterial pressure target of ≥65 mmHg"

• Mechanism: V1 receptor-mediated vasoconstriction — different pathway from noradrenaline's adrenergic mechanism → additive effect
• Benefit: allows noradrenaline dose reduction (catecholamine-sparing)
• Does not increase HR further (unlike epinephrine) — important in this patient already at HR 140
• Reduces noradrenaline requirements and may protect renal function (VASST trial)
• Do not exceed 0.03–0.04 U/min — higher doses cause mesenteric and coronary ischemia

3. Add Hydrocortisone (Corticosteroids)

"In patients with septic shock and ongoing requirement for vasopressor therapy, it is recommended to start intravenous corticosteroids with hydrocortisone at a dose of 200 mg/d often provided as 50 mg every 6 h."

• Ongoing vasopressor requirement despite fluids = indication
• Severe malaria + septic shock → relative adrenal insufficiency is very likely
• Cytokine storm in malaria suppresses adrenal response
• Corticosteroids restore vasopressor sensitivity (upregulate adrenergic receptors)

⚠️ Malaria-specific caution: High-dose glucocorticoids are harmful in cerebral malaria (increase coma duration, GI bleeding). But low-dose hydrocortisone (200 mg/day) for hemodynamic support in vasopressor-dependent septic shock is different from high-dose dexamethasone treatment of cerebral malaria — the former is guideline-supported and safe in this context. This patient is conscious/coherent (no cerebral malaria), so vasopressor-support dosing is appropriate.

4. Address Heart Rate 140 — Is It Contributing to Hypotension?

"Some patients, especially younger patients, have excessive tachycardia that limits diastolic filling time... short-acting IV β-blockers (esmolol) have shown encouraging results."

• Tachycardia is likely compensatory (trying to maintain BP)
• Underlying cause (malaria parasitemia, fever, hypovolemia) not yet resolved
• Do not give esmolol or rate control until you know cardiac function by echo — slowing HR in a volume-depleted, vasodilated patient will precipitate cardiac arrest
• Instead: treat the cause of tachycardia — fever control, fluid optimization, parasite clearance

5. Consider Epinephrine (Third-Line)

• Combined α + β agonist — adds inotropy + vasoconstriction
• Use when there is evidence of myocardial dysfunction (low cardiac output + vasodilation)
• Goldman-Cecil: "combination of norepinephrine + dobutamine results in similar mortality to epinephrine alone" — so either is acceptable
• Downside: increases lactate (β2-mediated glycogenolysis → lactate production) — do not interpret rising lactate on epinephrine as worsening tissue ischemia alone

• Dobutamine 2–20 μg/kg/min added to noradrenaline to increase inotropy

6. Interpret Lactate 3.2 and Set a Clearance Target

• If lactate failing to clear → escalate vasopressors, add second agent, reassess source control
• If lactate rising despite vasopressors → consider mesenteric ischemia, worsening AKI, or occult bleed
• Per Rosen's: "if lactate does not decrease at least 10% despite fluid resuscitation and vasopressor administration, particularly in the setting of echocardiographic evidence of dysfunction — consider inotrope"

7. Parallel Actions — Don't Forget

Summary: Refractory Shock Protocol

Noradrenaline alone → BP 90/60 persists
               ↓
Step 1: Reassess fluid status (PLR / POCUS)
        → If fluid-responsive: 250–500 mL bolus LR
        → If not: no more fluid
               ↓
Step 2: ADD Vasopressin 0.03 U/min (second vasopressor)
               ↓
Step 3: ADD Hydrocortisone 50 mg IV q6h
               ↓
Step 4: If still refractory → ADD Epinephrine OR Dobutamine
        (based on echo: vasodilatory vs. cardiogenic component)
               ↓
Step 5: Escalate to Meropenem (refractory shock = escalation trigger)
               ↓
Step 6: Serial lactate q2h — target ≥10% clearance per interval
               ↓
Step 7: If still refractory → ICU escalation, arterial line,
        consider angiotensin II, renal replacement therapy

Sources: Harrison's Principles of Internal Medicine 22E (2025) — Sepsis Management; Goldman-Cecil Medicine — Circulatory Therapy in Septic Shock

Vasopressin Infusion for This Patient (50 kg)

Standard Dose

Preparation & Infusion Rate

Standard Concentration: 20 units in 100 mL NS (= 0.2 units/mL)

Alternative Concentration: 40 units in 100 mL NS (= 0.4 units/mL)

Key Rules

Most Practical Setup for a Resource-Limited Setting